Cargando…

Prader-Willi syndrome: a single center's experience in Korea

PURPOSE: Prader-Willi syndrome (PWS) is a complex genetic disorder that results from the lack of paternally expressed genes in the chromosome 15q11-q13 region. This study was performed to delineate the clinical features of PWS infants and toddlers and the effects of two-year growth hormone (GH) trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yea Ji, Cheon, Chong Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Pediatric Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127393/
https://www.ncbi.nlm.nih.gov/pubmed/25114691
http://dx.doi.org/10.3345/kjp.2014.57.7.310
_version_ 1782330018860367872
author Kim, Yea Ji
Cheon, Chong Kun
author_facet Kim, Yea Ji
Cheon, Chong Kun
author_sort Kim, Yea Ji
collection PubMed
description PURPOSE: Prader-Willi syndrome (PWS) is a complex genetic disorder that results from the lack of paternally expressed genes in the chromosome 15q11-q13 region. This study was performed to delineate the clinical features of PWS infants and toddlers and the effects of two-year growth hormone (GH) treatment according to gender and age at the start of treatment. METHODS: The clinical characteristics and the results of the GH treatment were reviewed retrospectively for 30 PWS patients diagnosed by molecular genetic testing and clinical manifestations. RESULTS: The mean age at diagnosis with PWS was 13.7 months (2-47 months of age). All patients showed the characteristics of facial dysmorphism, including brown hair and almond-shaped eyes. Most patients showed developmental delays/mental retardation (93.3%), cryptorchidism (75%), feeding problems in infancy (73.3%), and neonatal or infantile hypotonia (66.7%). Among 30 patients, 14 PWS infants and toddlers had been treated with GH for more than two years. Two years of GH treatment resulted in an improvement in head circumference-standard deviation score (HC-SDS), body weight-SDS, insulin-like growth factor-1 (IGF-1) SDS, IGF binding protein-3 (IGFBP-3) SDS, lean body mass, and bone mineral content, especially in IGFBP-3 SDS and motor development in PWS patients younger than two years of age. There was significant increase in IGF-1 SDS and IGFBP-3 SDS among male PWS patients after GH treatment. CONCLUSION: Our study showed increases in IGFBP-3 SDS and an improvement in motor development among individuals under two years of age after GH treatment, and significant difference in IGF-1 SDS and IGFBP-3 SDS by gender.
format Online
Article
Text
id pubmed-4127393
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Pediatric Society
record_format MEDLINE/PubMed
spelling pubmed-41273932014-08-11 Prader-Willi syndrome: a single center's experience in Korea Kim, Yea Ji Cheon, Chong Kun Korean J Pediatr Original Article PURPOSE: Prader-Willi syndrome (PWS) is a complex genetic disorder that results from the lack of paternally expressed genes in the chromosome 15q11-q13 region. This study was performed to delineate the clinical features of PWS infants and toddlers and the effects of two-year growth hormone (GH) treatment according to gender and age at the start of treatment. METHODS: The clinical characteristics and the results of the GH treatment were reviewed retrospectively for 30 PWS patients diagnosed by molecular genetic testing and clinical manifestations. RESULTS: The mean age at diagnosis with PWS was 13.7 months (2-47 months of age). All patients showed the characteristics of facial dysmorphism, including brown hair and almond-shaped eyes. Most patients showed developmental delays/mental retardation (93.3%), cryptorchidism (75%), feeding problems in infancy (73.3%), and neonatal or infantile hypotonia (66.7%). Among 30 patients, 14 PWS infants and toddlers had been treated with GH for more than two years. Two years of GH treatment resulted in an improvement in head circumference-standard deviation score (HC-SDS), body weight-SDS, insulin-like growth factor-1 (IGF-1) SDS, IGF binding protein-3 (IGFBP-3) SDS, lean body mass, and bone mineral content, especially in IGFBP-3 SDS and motor development in PWS patients younger than two years of age. There was significant increase in IGF-1 SDS and IGFBP-3 SDS among male PWS patients after GH treatment. CONCLUSION: Our study showed increases in IGFBP-3 SDS and an improvement in motor development among individuals under two years of age after GH treatment, and significant difference in IGF-1 SDS and IGFBP-3 SDS by gender. The Korean Pediatric Society 2014-07 2014-07-23 /pmc/articles/PMC4127393/ /pubmed/25114691 http://dx.doi.org/10.3345/kjp.2014.57.7.310 Text en Copyright © 2014 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Yea Ji
Cheon, Chong Kun
Prader-Willi syndrome: a single center's experience in Korea
title Prader-Willi syndrome: a single center's experience in Korea
title_full Prader-Willi syndrome: a single center's experience in Korea
title_fullStr Prader-Willi syndrome: a single center's experience in Korea
title_full_unstemmed Prader-Willi syndrome: a single center's experience in Korea
title_short Prader-Willi syndrome: a single center's experience in Korea
title_sort prader-willi syndrome: a single center's experience in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127393/
https://www.ncbi.nlm.nih.gov/pubmed/25114691
http://dx.doi.org/10.3345/kjp.2014.57.7.310
work_keys_str_mv AT kimyeaji praderwillisyndromeasinglecentersexperienceinkorea
AT cheonchongkun praderwillisyndromeasinglecentersexperienceinkorea